• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 • 上一篇    下一篇

美罗培南与亚胺培南对重症肺炎的疗效及相关指标的影响

钱彦华,田静,李佳芮,杨焕芝   

  1. 昆明市第一人民医院,昆明市第一人民医院,昆明医科大学海源学院,昆明市第一人民医院
  • 收稿日期:2019-02-01 修回日期:2019-04-12 出版日期:2019-04-25 发布日期:2019-04-25

Effects of Meropenem and Imipenem on the Efficacy and Related Indicators of Severe Pneumonia

Qian Yanhua,, and   

  1. Department of Pharmacy,Kunming First Peopls Hospital, Yunnan Kunming 650034,,Haiyuan College,Kunming Medical University,Yunnan Kunming 650101,China,Department of Pharmacy,Kunming First Peopls Hospital, Yunnan Kunming 650034
  • Received:2019-02-01 Revised:2019-04-12 Online:2019-04-25 Published:2019-04-25

摘要: 目的:探讨美罗培南与亚胺培南对重症肺炎患者的临床疗效及血清CRP-U、PCT、IL-6等指标的影响。方法:抽取2017年1~12月某三甲综合医院呼吸内科病例200例(美罗培南组100例,亚胺培南组100例)进行回顾性统计分析,评价两药的临床疗效及对CRP-U、PCT、IL-6相关指标治疗前后的影响。结果:两种药物选择、用法用量、治疗疗程较合理,治疗后两组CRP-U、PCT、IL-6相关指标值均明显下降,有统计学意义(P<0.05);临床有效率美罗培南组85%、亚胺培南组78%,二者比较无统计学意义(P>0.05)。结论:美罗培南与亚胺培南是治疗重症肺炎的重要药物,临床需严格规范与合理使用碳青霉烯类抗菌药物。

Abstract: Objective: To investigate the effect of meropenem and imipenem on the clinical efficacy and serum CRP-U, PCT and IL-6 related indexes of severe pneumonia patients. Methods: 200 cases of respiratory medicine (100 cases of meropenem group and 100 imipenem group) in a three a general hospital during January to December 2017 were retrospectively analyzed to evaluate the clinical effect of two drugs and the effect on the treatment of CRP-U, PCT and IL-6. Results:The drug selection, usage and dosage, treatment course were more reasonable. After treatment, the values of CRP-U, PCT and IL-6 in the two groups decreased significantly (P<0.05), and the clinical effective rate of meropenem group was 85%, and imipenem group was 78%, no statistical significance (P>0.05). Conclusion:Meropenem and imipenem are important drugs for severe pneumonia.